Latest News on Dr reddy's
Showing of 0 - 10 from 95 results
Dr reddy's - Total results - 95
Sep 01, 2017
Sensex, Nifty rides on auto sales numbers, ends week on a highStrengthening for the third day, the benchmark Sensex went up 162 points to end at 31,892.23, a three-week high, while the Nifty closed short of 10,000
Aug 22, 2017
Sensex, Nifty make marginal gains, Infosys closes up tooSensex settled up 33 points, or 0.11 percent, at 31,291.85 while Nifty ended at 9,765.55, up 11.20 points
Aug 08, 2017
Sensex sinks 260 points, Nifty ends below 10,000 as Sebi clamps down on shell companiesAmong the sectoral indices, realty was the hardest hit, down 4.53 percent
Jul 28, 2017
Sensex, Nifty fall on profit booking in pharma, banking stocksOn a weekly basis, the Sensex climbed 280.99 points, or 0.87 Percent, while the Nifty gained 99.25 points, or 1 percent
Jul 27, 2017
Sensex hits new high, Nifty retreats from record level on F&O expiry daySensex closed marginally higher by 0.84 point at 32,383.30.
Jul 24, 2017
India Inc salary mismatch: Private CEOs get up to 1,200 times more than staff, PSU chiefs just 3-4 timesTCS saw the ratio between top-paid executive pay and the median employee remuneration rise to 515 times (from 460 times in previous year), while the same for Lupin stood at 1,263 times (though down from 1,317 times) for Chairman.
Mar 09, 2017
Dr Reddy's shares hit near three-year low, drops 4% as Duvvada unit receives 13 observations from US FDAThe Duvvuda unit makes cytotoxic and hormonal injectables. It is an important unit for Dr Reddy’s
Nov 07, 2016
Hillary win may pose pricing challenges for pharma cos: ReportA Democrat sweep in US polls may pose even greater pricing challenges for the pharma industry and pave the way for tighter pricing regulations for both brand name and generic drugs, according to a report.
Oct 10, 2016
Dr Reddy's launches generic Lamotrigine tablets in USThe company's product is generic version of GSK Group of companies' Lamictal tablets
Sep 16, 2016
Dr Reddy's inks pact with US-based Amgen to market three drugs in IndiaUnder the terms of collaboration, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India